Anxiety News and Research

Latest Anxiety News and Research

Sexually rejected male fruit flies binge on alcohol more than sexually satisfied peers: Study

Male fruit flies whose sexual advances are rejected by females, turn to alcohol finds a new study. Scientists at the University of California, San Francisco discovered that rejected male flies have a tiny molecule in their brain that pushes them to drink far more than their sexually satisfied counterparts. The levels of the molecule, neuropeptide F, were higher in sexually satisfied males than in those who got no sex, leading scientists to speculate that their work could shed light on brain mechanisms behind human addiction. A similar human molecule - neuropeptide Y - may also link social triggers to behaviors such as heavy drinking and drug abuse, according to the study published in Science journal.

18 Mar 2012

HHS Secretary launches new educational initiative, MyCare

Health and Human Services (HHS) Secretary Kathleen Sebelius today unveiled "MyCare," a collection of online personal video and blog stories of Americans helped by the Affordable Care Act.

17 Mar 2012

Post-chemotherapy cognitive changes impact lives of Asian breast cancer patients

A recent study by National University of Singapore (NUS) researchers revealed that Asian breast cancer patients who had received or were undergoing chemotherapy treatment showed symptoms of "chemobrain", in which they encounter memory loss, difficulty in decision making and speech problems.

16 Mar 2012

Neuropeptide F in the fly's brain governs behavior linked with addiction

Sexually deprived male fruit flies exhibit a pattern of behavior that seems ripped from the pages of a sad-sack Raymond Carver story: when female fruit flies reject their sexual advances, the males are driven to excessive alcohol consumption, drinking far more than comparable, sexually satisfied male flies.

16 Mar 2012

Depression increases risk of death in PCI patients

Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died than non-depressed patients. The findings were independent of age, gender, clinical characteristics, anxiety and the distressed (Type D) personality.

16 Mar 2012

Teva gets exclusive 180 days to market generic antidepressant and anti-anxiety pill Lexapro

Teva Pharmaceutical Industries Ltd. Has won U.S. approval to sell the first generic version of Lexapro for depression and anxiety. Teva has been granted a 180-day exclusivity, so no other firm can market the generic medication in the United States in that timeframe, the Food and Drug Administration (FDA) said in a news release.

15 Mar 2012

Fear of flying can be cured independently of YOH or after 4 sessions of VRET

This randomized controlled trial shows that fear of flying can be cured independently of drug condition [yohimbine hydrochloride (a noradrenaline agonist) or placebo] after 4 sessions of virtual reality exposure therapy (VRET).

15 Mar 2012

Many women experience memory problems during menopause, confirms study

The difficulties that many women describe as memory problems when menopause approaches are real, according to a study published today in the journal Menopause, the journal of the North American Menopause Society.

15 Mar 2012

AT-1001 shows promise in treating drug addiction

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

15 Mar 2012

Exercise training can reduce worry symptoms among GAD patients

This study demonstrates that exercise training, including resistance exercise training, is a feasible, low-risk treatment that can potentially reduce worry symptoms among generalized anxiety disorder (GAD) patients and may be an effective adjuvant, short-term treatment or augmentation for GAD.

15 Mar 2012

Teva commences commercial launch of Escitalopram Oxalate Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets.

15 Mar 2012

Viewpoints: Sandra fluke on slurs; Shifting the cost of uncompensated care

(D)espite the misinformation being spread, the regulation under discussion has absolutely nothing to do with government funding: It is all about the insurance policies provided by private employers and universities that are financed by individual workers, students and their families -- not taxpayers.

14 Mar 2012

Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.

14 Mar 2012

Uncovering the science behind generations of mental illness

Sometimes the most interesting way to digest scientific information is within the context of personal experiences. Likewise, the story of someone's personal journey or struggle can take on broader significance when melded with the insights of scientific knowledge.

14 Mar 2012

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

13 Mar 2012

Root cause of dental phobia

Women in their forties are more likely to have dental anxiety than any other age group according to a University of Sydney study into dental anxiety and phobia.

11 Mar 2012

Concerns about aging in good health

Do men harbour concerns about aging in good health? Do they confide these concerns to their physicians? Are men's concerns the same as women's? The answers to these questions can be found in a large cross-sectional survey of 2325 Canadian men, aged 55 to 97 years old, led by Dr. Cara Tannenbaum, Geriatrician and the Michel Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging at the Institut universitaire de gériatrie de Montréal (IUGM) which is affiliated with the Université de Montréal.

10 Mar 2012

Heart rate lowering drug may reduce “implicit” racial prejudices: Study

It was found that volunteers given the beta-blocker, used to treat chest pains and lower heart rates, scored lower on a standard psychological test of “implicit” racist attitudes. They appeared to be less racially prejudiced at a subconscious level than another group treated with a “dummy” placebo pill.

8 Mar 2012

CB2 receptor involved in regulating impulsive behaviour

A new study lead by the Neuroscience Institute of Alicante reveals how manipulating the endocannabinoid system can modulate high levels of impulsivity. This is the main problem in psychiatric illnesses such a schizophrenia, bipolar disorder and substance abuse.

8 Mar 2012

Loss of glutamate receptor linked to negative effects of chronic stress

Chronic stress has a more powerful effect on the brain during adolescence than in adulthood and now there's proof at the molecular level, according to findings published in Neuron by University at Buffalo researchers.

8 Mar 2012